C-MYC is a well-known oncogene in lymphomas and is overexpressed in ENKTL, likely driven by LMP1 and EBV infection and causing upregulation of downstream targets EZH2 and RUNX3, the latter of which is a master transcriptional regulator and a putative oncogene in ENKTL [22,67,68]. The gene discussed is EZH2; the disease is lymphoma.